[Diagnosis and therapy for beta2-microglobulin amyloidosis in the K/DOQI guideline].
According to the Kidney disease outcomes quality initiative (K/DOQI) guideline, in order to decrease risk of beta2-microglobulin amyloidosis, noncuprophane (EVIDENCE), high-flux dialyzers (OPINION) should be used. No currently available therapy, except kidney transplantation, can stop disease progression of beta2-microglobulin amyloidosis or provide symptomatic relief (EVIDENCE). Screening for beta2-microglobulin amyloidosis, including measurement of serum levels of beta2-microglobulin, is not recommended (OPINION).
Higuchi
Noboru
N
Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences.
Maruyama
Hiroki
H
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000327:Adsorption; D000686:Amyloidosis / Q000175:diagnosis* / Q000209:etiology / Q000517:prevention & control / Q000628:therapy*; D001706:Biopsy; D018450:Disease Progression; D019317:Evidence-Based Medicine; D006464:Hemoperfusion / Q000379:methods; D006801:Humans; D007150:Immunohistochemistry; D016030:Kidney Transplantation; D008567:Membranes, Artificial; D011108:Polymers; D017410:Practice Guidelines as Topic; D006435:Renal Dialysis / Q000009:adverse effects* / Q000379:methods*; D013450:Sulfones; D001613:beta 2-Microglobulin / Q000378:metabolism*
D000305:Adrenal Cortex Hormones; D008567:Membranes, Artificial; D011108:Polymers; D013450:Sulfones; D001613:beta 2-Microglobulin; C017662:polysulfone P 1700